Koraya et al. [7] have recently proposed that this potential clinical benefit of HER2 blockade in the adjuvant setting in tumors classified as HER2 might be explained by the hypothesis that the cancer stem cell expresses HER2. This evidence concerns the gene ERBB2 and cancer.